• Latest Posts

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

More News! 4 Jan 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

Interview 15 Nov 2017

Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

More News! 1 Nov 2017

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis


Austrian Researchers Identify Target for Treatment of Multiple Sclerosis

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B